# A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

> **NCT05914116** · PHASE1,PHASE2 · RECRUITING · sponsor: **DualityBio Inc.** · enrollment: 862 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** DB-1311
- **DRUG:** Lopinavir and Ritonavir Tablets
- **DRUG:** itraconazole
- **DRUG:** Enzalutamide
- **DRUG:** Abiraterone

## Key facts

- **NCT ID:** NCT05914116
- **Lead sponsor:** DualityBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-17
- **Primary completion:** 2027-12
- **Final completion:** 2028-05
- **Target enrollment:** 862 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05914116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05914116, "A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05914116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*